Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Inogen Earnings Call: Key Takeaways

Inogen is undergoing a strategic pivot, divesting its rental business and implementing a $20 million cost reduction program to offset international softness and return to profitability.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthUS sales $42.2M (up 3.8%); International sales declined 9% to $35M.
Mgmt ConfidenceConfident in long-term opportunity but acknowledged need for urgency and discipline.
Demand VisibilitySoftness in European capital spending expected to continue into fourth quarter.
Margin TrendsAdjusted gross margin 44.2%, down from 45.9% due to international mix.
Op. Leverage$20M annualized savings targeted by 2027 to improve capital efficiency.
Vol vs PricePOC unit volume increased nearly 6%; new products added 250 bps growth.
Segment GrowthUS growth driven by distributor demand; International lagged due to inventory management.
New ClientsStrategically partnering with US distributors; expanding into Asia Pacific and Latin America.
Capex & DebtDivested rental business for $24.8M; $97.7M cash; zero debt; $45M buyback.
CommentaryShifting focus to broader respiratory portfolio including sleep and airway clearance.
New LaunchesAurora and Boxy products starting to contribute to growth in adjacent markets.

Growth

Total revenue fell 2.4% to $77.2M; US sales grew 3.8% while international sales declined 9%.

Outlook

FY2026 revenue guided to $298M-$301M with $20M annualized savings expected by end of 2027.

Risks

Management refused all live Q&A, preventing scrutiny on international capital spending softness and goodwill impairment.

Source

The company's earnings call, NASDAQ: INGN, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Inogen Inc: key numbers

Share price
$5.63Close, Nov 16
Market cap
$146M
Shares outstanding
26MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Inogen Inc

All →
4:08 PM ET 10-Q
Financial Results

Inogen Q3 2026 Results: Net Loss of $16.2M, Loss Widens

Inogen Inc. reported a net loss of $16.2 million for the third quarter of 2026, compared to a $5.3 million loss in the prior year, driven by a $10.6 million impairment charge. Total revenue for the quarter decreased slightly to $77.2 million, while the company's cash position declined to $81.8 million as of September 30, 2026.

Key figure
Net loss $16.2M
4:13 PM ET 8-K
Leadership Change

Inogen Leadership Change

Inogen appointed current COO Andy Reding as President and CEO and a member of the Board of Directors, effective October 30, 2026. He succeeds Kevin R.M. Smith, whose role as an officer and employee ended on the same date. The transition occurs as the company focuses on a more streamlined commercial model following the divestiture of its U.S. rental business.

4:10 PM ET 8-K
Divestiture

Inogen Divestiture to Rotech Healthcare Inc. for $24.8M

Inogen agreed to sell substantially all assets of its U.S. oxygen rental business to Rotech Healthcare for an estimated $24.8 million. The divestiture is intended to streamline Inogen's commercial model and shift focus toward its product supply business, supported by a new long-term supply agreement with Rotech. Upon closing, Inogen will also increase its share repurchase authorization from $30 million to $45 million.

Value
$24.8M
Counterparty
Rotech Healthcare Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.